VacZine Analytics  
MarketVIEW: Ross River Virus vaccines

Published: July 2013

Ross River Virus (RRV) is a mosquito-borne alphavirus (Togaviridae) mainly indigenous to Australia and the Western Pacific region. Infection with the virus can cause joint pain (polyarthritis/arthralgia) in humans which is reported to persist from between 3 months to a year or more. There is no cure for RRV disease, and treatment is confined to the management of pain. In Australia, several thousand cases occur each year with variability across territories.

Due to its high morbidity and impact on quality of life, Baxter Bioscience mainly in concert with Queensland University of Technology, Brisbane have been developing and inactivated Ross River virus vaccine. A first Phase 3 study started in male and female subjects aged >16 years initiated in April 2011 with licensure predicted in 1-2 years.

This MarketVIEW product is a comprehensive commercial opportunity assessment detailing the potential market for a Ross River virus vaccine with a patient based value/volume forecast for all Australians and "at risk" areas only to 2030. The potential use of the vaccine in travelling populations is also explored along with a review of latest epidemiology, clinical development update and rationale for vaccine approach.

THIS PRODUCT IS COMPOSED OF SUMMARY PRESENTATION + 1 MODEL (optional)

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV047 Click here>>
Discounted option:
*Prices are quoted for either presentation or forecast model separately and are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2013 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains